Taysha Gene Therapies Inc.

11 days ago · seekingalpha.com

Taysha Gene Therapies offers a speculative opportunity, hinging on durable clinical gains, safety, and disciplined execution for TSHA-102 in Rett syndrome. TSHA's $455.4M cash runway extends into H2 2028, supporting pivotal data collection and manufacturing scale-up without immediate dependence on accelerated regulatory filing. TSHA-102's early data show deepening, durable functional gains in Rett patients, but pivotal efficacy, safety, and manufacturing qualification remain key investment inflection points.

1 month ago · seekingalpha.com

Taysha Gene Therapies, Inc. (TSHA) Q2 2026 Earnings Call Transcript

1 month ago · marketbeat.com

Taysha Gene Therapies NASDAQ: TSHA said it completed dosing in its REVEAL pivotal trial and ASPIRE trial for TSHA-102, its gene therapy candidate for Rett syndrome, while preparing for a potential biologics license application submission.

1 month ago · globenewswire.com

Completed dosing in the REVEAL pivotal (N=17) and ASPIRE (N=4) trials evaluating TSHA-102 for Rett syndrome; expect to report topline data from 6 ‑ month interim analysis and FDA feedback on the BLA submission pathway in 1H 2027

3 months ago · seekingalpha.com

Taysha Gene Therapies (TSHA) remains a "Buy," driven by strong TSHA-102 data in Rett Syndrome and pivotal trial progress. TSHA-102 achieved 100% response rate at 12 months in Part A, surpassing the 33% response threshold needed for regulatory submission. Alignment with the FDA on pivotal trial endpoints and interim analysis could enable an accelerated BLA submission in 1H 2027.

3 months ago · globenewswire.com

Recently disclosed longer-term REVEAL Part A data demonstrated broad, multi-domain functional impact that deepened over time through ≥12 months post-TSHA-102 regardless of age or disease severity

3 months ago · globenewswire.com

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 32,500,001 shares of its common stock at a price to the public of $6.00 per share and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase 833,333 shares of its common stock at an offering price of $5.999 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 5,000,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The gross proceeds from the offering to Taysha are expected to be approximately $200.0 million, before deducting underwriting discounts and commissions and other offering expenses, excluding any exercise of the underwriters' option to purchase additional shares. The offering is expected to close on or about June 26, 2026, subject to customary closing conditions.

3 months ago · globenewswire.com

DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that it has commenced an underwritten public offering of $200.0 million shares of its common stock and, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock. All of the securities will be offered by Taysha. Taysha also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering under the same terms and conditions (including shares underlying the pre-funded warrants). The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

3 months ago · seekingalpha.com

Taysha Gene Therapies, Inc. (TSHA) Discusses Longer-Term Clinical Data and Program Update for TSHA-102 in Rett Syndrome Transcript

4 months ago · globenewswire.com

DALLAS, June 05, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced that, on June 1, 2026, the Compensation Committee of Taysha's Board of Directors granted four new employees, in the aggregate, restricted stock units (RSUs) representing 714,700 shares of the Company's common stock and an option to purchase 468,600 shares of the Company's common stock in connection with their employment.